Minimal residual disease in multiple myeloma: Benefits of flow cytometryIrina Galtseva, Л. П. Менделеева, Yulia Davydova et al.|International Journal of Laboratory Hematology|2017Cited by 10
Efficacy of Maintenance Therapy Following Auto-HSCT Depending on MRD Status in Patients with Multiple MyelomaMaxim Solovev, Savchenko Vg, Л. П. Менделеева et al.|Blood|2018Cited by 9
Interim results of the Ph-negative acute lymphoblastic leukemia treatment in adult patients (results of Russian research group of ALL treatment (RALL))Е. Н. Паровичникова, Savchenko Vg, V. V. Troitskaya et al.|DOAJ (DOAJ: Directory of Open Access Journals)|2015Cited by 9
Maintenance Therapy after Autologous Haematopoietic Stem Cell Transplantation (auto-HSCT) in Multiple Myeloma Patients with and without Minimal Residual Disease (MRD)Maxim Solovev, Savchenko Vg, Л. П. Менделеева et al.|Blood|2016Cited by 6
Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual diseaseM. V. Solovyev, Savchenko Vg, Л. П. Менделеева et al.|Terapevticheskii arkhiv|2017Cited by 4